Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer-Reference-Cited by-同舟云学术

Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer

Published:2021-04-20 Issue:14 Volume:27 Page:4012-4024
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Kazi Aslamuzzaman,Chen Liwei^ORCID,Xiang Shengyan,Vangipurapu Rajanikanth^ORCID,Yang Hua,Beato Francisca,Fang Bin,Williams Terence M.^ORCID,Husain Kazim,Underwood Patrick^ORCID,Fleming Jason B.,Malafa Mokenge,Welsh Eric A.^ORCID,Koomen John^ORCID,Trevino José,Sebti Saïd M.

Funder

NIH

Joseph & Ann Matella Fund for Pancreatic Cancer Research

H. Lee Moffitt Cancer Center & Research Institute

NCI

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhanced Anti-tumor Effect of Flavopiridol in Combination With Gemcitabine in Pancreatic Cancer;Anticancer Research;2024-02-29

2. Omics-based molecular classifications empowering in precision oncology;Cellular Oncology;2024-01-31

3. An innovative nanoformulation utilizing tumor microenvironment-responsive PEG-polyglutamic coating and dynamic charge adjustment for specific targeting of ER stress inducer, microRNA, and immunoadjuvant in pancreatic cancer: In vitro investigations;International Journal of Biological Macromolecules;2024-01

4. Visceral Cancer Pain;Visceral Pain;2024

5. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super‐enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis‐generating study;Clinical and Translational Medicine;2023-11-30